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Abstract
Background: Biliary tract cancer is a rare malignancy that carries poor prognosis. Complete surgical resection is the
only curable treatment. However, biliary tract cancer patients are often diagnosed with advanced stages and treated in
systemic chemotherapy or palliative treatment settings rather than curative surgery.
Case presentation: This case report describes a pathological complete response of advanced biliary tract cancer
achieved after 2 years of intensive combined chemotherapy with gemcitabine and S-1. A 70-year-old female patient who
developed severe stenosis in the middle common bile duct with para-aortic lymph nodes swelling was diagnosed with
advanced extrahepatic biliary tract cancer that includes metastatic para-aortic lymph nodes and treated with combined
chemotherapy of gemcitabine and S-1. After 32 courses of the combined chemotherapy, substantial shrinkage of these
enlarged lymph nodes were confirmed and she underwent pylorus-preserving pancreaticoduodenectomy. The
pathological examination revealed no viable neoplastic cells in the common bile duct or lymph nodes. She did not
receive any further adjuvant chemotherapy. No recurrent lesions have been detected for 48 months after the primary
surgery.
Conclusions: This case shed light on the probability of conversion and/or adjuvant surgery for biliary tract cancer with
novel systemic chemotherapy regimens.
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Background
Biliary tract cancer (BTC) is rare and often aggressive
malignancy. BTC includes four distinct categories of
adenocarcinoma intrahepatic cholangiocarcinoma, extra-
hepatic cholangiocarcinoma, gallbladder cancer (GBC),
and ampullary carcinoma. Complete surgical resection
only offers patients a chance for cure. However, even if
curative intent surgery is applied to resectable BTC pa-
tients, 5-year survival rates still remain low: 33.1% for
bile duct cancer, 52.8% for ampullary cancer, and 41.6%
for gallbladder cancer [1]. BTC patients are often diag-
nosed with advanced stages in which tumor metastasizes
to distant organs or involves adjacent tissue and treated
with systemic chemotherapy. Gemcitabine has been the
mainstay of the systemic chemotherapy treatment of bil-
iary tract cancer. Moreover, recent advances in develop-
ment of chemotherapy regimens have gained additional
survival benefits for advanced BTC patients. The com-
bination of gemcitabine (GEM) and cisplatin (GC ther-
apy) has begun to be considered as the standard of care
for BTC treatment. Meanwhile, S-1 is often used as
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second-line treatment for advanced BTC that is refrac-
tory to GEM treatment. The use of the combined
chemotherapy of GEM and S-1 for advanced BTC has
been examined recently and shown favorable results.
This case report describes that a pathological complete
response was obtained by curative surgery after 32
courses of combined chemotherapy of GEM and S-1 for
a patient who was diagnosed with extrahepatic biliary
tract cancer with para-aortic lymph node metastasis.
Case presentation
A 70-year-old female patient was admitted to the hospital
because of 2 weeks of persisting epigastric discomfort. She
had medical history of untreated choledocolithiasis for
4 years. Physical examination was only remarkable for ten-
derness in the right upper quadrant area. The patient’s
white blood cell count was 5500/μl, hemoglobin was
12.4 g/dl, and platelet count was 190,000/μl. Any disorders
for liver function tests were not detected. Serum bilirubin
level was also within normal range. Serum tumor marker
values such as CEA and CA 19-9 were not elevated. How-
ever, CRP was elevated to 4.8 mg/dl. CT scan revealed
dilatation of intra and extra hepatic bile ducts, gallbladder
stones and gallbladder wall thickness. No mass lesions in
the head of the pancreas or in the biliary tract were de-
tected except for enlarged swollen intra abdominal and
para-aortic lymph nodes (Fig. 1a, b). Given these findings,
she was initially diagnosed with acute cholecystitis. Al-
though percutaneous transhepatic gallbladder drainage
(PTGBD) was safely performed, common bile duct was
not radiographically visualized. Magnetic response cholan-
giopancreatograpy (MRCP) showed severe stenosis in the
middle extrahepatic bile duct with dilatation of the intra-
hepatic bile ducts (Fig. 2). Histological diagnosis of adeno-
carcinoma of the middle extrahepatic bile duct was made
by endoscopic transpapillary bile duct biopsy (Fig. 3). A
covered self-expandable metallic stent (ZENOSTENT cov-
ered 10 mm× 80 mm; Zeon Medical Inc., Tokyo, Japan)
was placed endoscopically. Based on these findings, she
was diagnosed with BTC with para-aortic lymphnodes
metastasis and treated with a combined chemotherapy
regimen of GEM and S-1. 1000 mg/m2 of GEM was intra-
venously administered at day 1 and 8, and 80 mg/day of S-
1 was orally given for 14 days followed by 7 days of rest,
repeated every 3 weeks. After the six courses, enlarged
para-aortic lymph nodes began to shrink. Adverse effects
included grade 2 suppression of bone marrow function,
hair loss, and GI symptoms such as diarrhea, and vomiting
that were tolerable and managed by reducing administra-
tion dose to 80% of the initial dosage without discontinu-
ation of the chemotherapy.
Finally after 32 courses of the combined chemother-
apy, many enlarged lymph nodes were reduced by more
than 50% in diameter (Fig. 4a, b). The patient agreed to
undergo curative intent surgery 2 months after the final
dose administration. Peritoneal lavage cytology did not
detect any adenocarcinoma cells. Intra operative frozen
section analysis of para-aortic lymph node station 16b1
did not detect any tumor cells, either. Therefore,
pylorus-preserving pancreaticoduodenectomy was safely
performed. Hepatic duct was transected at the level of
1.0 cm below the union of left hepatic duct and right
Fig. 1 a An abdominal CT scan image shows dilatation of intrahepatic biliary duct. No mass lesions are seen in the liver. b A CT scan image
shows multiple para-aortic lymph nodes swelling and multiple gallbladder stones with gallbladder wall thickness
Fig. 2 A MRCP image shows sever stenosis in the middle common
bile duct (arrow). Gallbladder was not clearly visualized
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hepatic duct. Twenty-seven lymph nodes including sta-
tions 6, 8a, 12a, 12p, 13a, 13b, 16inter, 16b1, and17a were
harvested. Pathological examination of the resected speci-
men showed no residual neoplastic cells in bile duct,
cystic duct, and gallbladder. Fibrosis in the bile duct with
the presence of plasma cells and macrophages was ob-
served (Fig. 5a–c). Para-aortic lymph node specimens also
showed replacement fibrosis and aggregates of macro-
phages, but did not show any residual tumor cells. (Fig. 6a,
b). Postoperative complications included grade B pancre-
atic fistula that was treated conservatively. The patient
was discharged on postoperative day 45. The patient did
not agree to receive adjuvant chemotherapy. 48 months
after the surgery, the patient is in a good condition, and
no suspicious recurrent lesions have been detected.
Discussion
For those whose stage is beyond the scope of curative sur-
gery, systemic chemotherapy is chosen to apply. GEM has
achieved improved response rates and survival benefit
since its approval for BTC treatment [2–4]. For example,
GEM-based chemotherapy such as GC therapy achieves
good antitumor activity. Recent results from a multicenter,
randomized phase III trial, the UK ABC-02 trial that eval-
uated GEM with or without cisplatin in patients with ad-
vanced or metastatic BTC have demonstrated a clear
survival advantage (hazard ratio 0.68, P = 0.002) for the
combination of GEM and cisplatin (GC regimen) without
added clinically intolerable toxicity [5]. A Japanese multi-
center phase III trial using the same regimen has also
shown favorable results consistent with the result of ABC-
Fig. 3 Endoscopic transpapillary bile duct biopsy specimen shows infiltration of poorly differentiated adenocarcinoma cells beyond muscularis mucosa
a low power field image, b high power field image
Fig. 4 Abdominal CT images scan showing swollen regional lymph nodes before chemotherapy (a, b), and after 32 courses of chemotherapy (c, d).
Maximal diameter measurements of the regional lymph nodes were decreased by more than 50%: from 20 mm before chemotherapy (a) to 5 mm
after chemotherapy (c) for celiac lymph node #9 and from 20 mm before chemotherapy (b) to 8 mm after chemotherapy (d) for para-aortic lymph
node #16a2 inter
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02 study: the median survival and overall response rate of
GC vs. GEM alone were 11.2 vs. 7.7 months and 19.5 vs.
11.9%, respectively [6]. Along with these results, GC regi-
men has been considered as new standard regimen for ad-
vanced BTC. Meanwhile, S-1 is an oral fluoropyrimidine
anticancer drug designed to enhance the anticancer activ-
ity of fluorouracil and reduce its gastrointestinal toxicity
[7]. S-1 monotherapy has already shown its anticancer ef-
fect against BTC with a 35% of response rate [8]. Based on
this result, in 2013, a multicenter phase II study that com-
pares GEM alone, and a combination chemotherapy with
GEM and S-1 (GS regimen) was conducted, reporting that
GS regimen showed a 36.4% response rate and mild tox-
icity for patients with advanced biliary tract cancer [9]. A
comparison study between GS and GC regimens for ad-
vanced BTC is currently ongoing in a randomized setting
(JCOG1113, UNIM000010667).
On the other hand, data is derived from small
retrospective trials and case reports about neoadju-
vant and conversion chemotherapy of BTC. Kato et al.
revealed that GEM regimen is able to downsize tu-
mors towards resectable stages and lead to produce
more R0 resections than the control group [10]. A
few cases of successful conversion chemotherapy from
initially unresectable BTC to resectable have been re-
ported [11–13]. No general consensus about this issue
has been made.
The most astonishing point in this case report is the
achievement of pCR both in the primary tumor lesion
and metastatic lymph nodes, although preoperative diag-
nosis was not made. Preoperative CT evaluation de-
tected 13 lymph nodes, maximum short axis diameter
(MSAD) of which is larger than 10 mm. The shapes of
these lymph nodes are irregular round rather than flat
shape. MSAD of lymph node station 8a was 30 mm.
Nodal enlargement of station 16b1 was also found. Al-
though there is no agreement on the definition of the
threshold of nodal enlargement for metastasis, findings
such as total numbers of enlarged nodes, MSAD, and
wide spread of nodal enlargements strongly suggested
Fig. 5 Macrographs of the resected specimen show erosion of biliary mucosa and disappearance of biliary mucosa cells in the middle common
bile duct (a, b). Histopathological examination reveals no residual cancer cells in the middle common bile duct (c)
Fig. 6 Resected lymph node shows fibrosis with histiocyte infiltration (a, b)
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lymph node metastasis rather than nodal enragement
caused by cholecystitis. Furthermore, the presence of scar-
ring without tumor cells in the harvested lymph node spe-
cimen most likely represents complete response to
chemotherapy. Previous reports addressed pathological
complete response after chemotherapy for advanced BTC.
In a single center phase II study that evaluated combin-
ation chemotherapy of GEM and oxaliplatin (OXIGEM)
for advanced GBC patients, Sharma et al. [14] reported
one pCR. Another case report also showed one pCR case
of BTC with five courses of the OXIGEM regimen [15].
Walker et al. reported that a case of pCR for locally ad-
vanced common bile duct (CBD) cancer was achieved
with GC regimen [16]. Lim et al. also reported that GS
regimen produced pathological complete response for
CBD cancer and radiographic disappearance of liver me-
tastasis [17]. However, none of these reports achieved
pCR of the metastatic lesion along with the primary lesion
as described in this report. This patient was not initially
treated in the neoadjuvant setting. Overwhelming re-
sponse made her switch to undergo curative intent sur-
gery after 2 years of the chemotherapy treatment. It might
be possible that this patient had unique cancer profile and
responded to the chemotherapy very well.
Conclusions
We experienced a patient with advanced BTC who was
treated with GEM plus S-1 and achieved pCR. GS regi-
men may be applicable for advanced BTC. Further cases
treated with GS regimen are needed to evaluate its efficacy
as conversion chemotherapy regimen for advanced and
unresectable BTC.
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